Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: A retrospective study

Blood Cells, Molecules, and Diseases

Volumn 49, Issue 3-4, 2012, Pages 133-135

  Ricchi, Paolo ^a   Ammirabile, Massimiliano ^a   Costantini, Silvia ^a   Di Matola, Tiziana ^b   Spasiano, Anna ^a   Genna, Maria Ludovica ^a   Cinque, Patrizia ^a   Prossomariti, Luciano ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b UOC Clinical Pathology   (Italy)

Author keywords

Hyperuricemia; Kidney stones; Risk factors; Splenectomy; Thalassemia

Indexed keywords

CREATININE; URIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ERYTHROBLAST; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; HYPERURICOSURIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; THALASSEMIA; URIC ACID BLOOD LEVEL; UROGRAPHY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BETA-THALASSEMIA; CREATININE; ERYTHROBLASTS; ERYTHROCYTE COUNT; ERYTHROCYTES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERURICEMIA; KIDNEY CALCULI; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SPLENECTOMY; URIC ACID;

EID: 84865983118     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.05.012     Document Type: Article

References (17)

1. Aldudak B., Karabay B.A., Noyan A., Ozel A., Anarat A., Sasmaz I., Kilinc Y., Gali E., Anarat R. Renal function in pediatric patients with beta-thalassemia major. Pediatr. Nephrol. 2000, 15:109-112.
2. Cetin T., Oktenli C., Ozgurtas T., Yenicesu M., Sanisoglu S.Y., Oguz Y., Yildiz O., Kurt I., Musabak U., Bulucu F., Kocar I.H. Renal tubular dysfunction in beta-thalassemia minor. Am. J. Kidney Dis. 2003, 42:1164-1168.
3. Ali D., Mehran K., Moghaddam A.G. Comparative evaluation of renal findings in beta-thalassemia major and intermedia. Saudi J. Kidney Dis. Transpl. 2008, 19:206-209.
4. Smolkin V., Halevy R., Levin C., Mines M., Sakran W., Ilia K., Koren A. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr. Nephrol. 2008, 23:1847-1851.
5. Halabe A., Sperling O. Uric acid nephrolithiasis. Miner. Electrolyte Metab. 1994, 20:424-431.
6. Kossiva L., Paterakis G., Tassiopoulos S., Papadhimitriou S.I., Voukouti E., Gligori I., Rombos Y. Decreased expression of membrane alpha4beta1, alpha5beta1 integrins and transferrin receptor on erythroblasts in splenectomized patients with beta-thalassemia intermedia. Parallel assessment of serum soluble transferrin receptors levels. Ann. Hematol. 2003, 82:579-584.
7. Ricchi P., Ammirabile A., Costantini S., Di Matola T., Verna R., Diano A., Foglia M.C., Spasiano A., Cinque P., Prossomariti L. A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study. Ann. Hematol. 2012, 91:905-909.
8. Taher A.T., Musallam K.M., Karimi M., El-Beshlawy A., Belhoul K., Daar S., Saned M.S., El-Chafic A.H., Fasulo M.R., Cappellini M.D. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010, 115:1886-1892.
9. Rule A.D., Krambeck A.E., Lieske J.C. Chronic kidney disease in kidney stone formers. Clin. J. Am. Soc. Nephrol. 2011, 6:2069-2075.
10. Taher A.T., Musallam K.M., El-Beshlawy A., Karimi M., Daar S., Belhoul K., Saned M.S., Graziadei G., Cappellini M.D. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br. J. Haematol. 2010, 150:486-489.
11. Mazzali M., Hughes J., Kim Y.G., Jefferson J.A., Kang D.H., Gordon K.L., Lan H.Y., Kivlighn S., Johnson R.J. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
12. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol. 2005, 16:3553-3562.
13. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
14. Neogi T. Asymptomatic hyperuricemia: perhaps not so benign?. J. Rheumatol. 2008, 35:734-737.
15. Taher A.T., Musallam K.M., Karimi M., El-Beshlawy A., Belhoul K., Daar S., Saned M., Cesaretti C., Cappellini M.D. Splenectomy and thrombosis: the case of thalassemia intermedia. J. Thromb. Haemost. 2010, 8:2152-2158.
16. Ricchi P., Lanza A.G., Ammirabile M., Costantini S., Cinque P., Spasiano A., Di Matola T., Di Costanzo C.G., Pagano L., Prossomariti L. Hepatitis C virus distribution and clearance following interferon-monotherapy among thalassaemia major and intermedia patients. Br. J. Haematol. 2011, 155:524-527.
17. Lai M.E., Vacquer S., Carta M.P., Spiga A., Cocco P., Angius F., Mandas A., Dessì S. Thalassemia intermedia is associated with a proatherogenic biochemical phenotype. Blood Cells Mol. Dis. 2011, 46:294-299.